In the "Executive Decision" segment, Cramer spoke with Alan Shortall, CEO of Unilife (UNIS), maker of clinical safety syringes. Cramer panned the stock on April 9, but welcomed Shortall to the show to prove him wrong. Shortall said there are over 3 million needle injuries around the world every year, and his company's patented safety syringe has validated technology to reduce those injuries. He demonstrated how Unilife's syringe contains a retractable needle, thereby eliminating the possibility of injuries. Shortall said that there are over 2.5 billion pre-filled syringed produced every year, and Unilife is on track ramp up production to 800 to 900 million units per year in just the next five to six years. He said Unilife's gross margins are also better than transitional syringes given that its partners absorb most of the marketing costs. When asked about the company's volatile share price when it came public, Shortall explained that due to a glitch in the IPO, some of the company's Australian shares did not transfer correctly to the NASDAQ, causing a shortage, and a spike in the share price. After hearing Shortall's case, and seeing the Unilife's products first hand, Cramer said he'd blessed the stock as a speculation, given that it still has a long way to go towards becoming a large medical device company, and its product offerings, while patented, are still narrow in scope.
UNS Price at posting:
$1.09 Sentiment: None Disclosure: Held
